The Montreal Heart Institute (MHI) has announced positive, clinically persuasive results from the COLCORONA clinical trial of orally administered drug, colchicine, for treating Covid-19.

The contact-less, randomised, double-blind, placebo-controlled clinical trial was conducted in an at-home setting in Canada, US, Europe, South America and South Africa.

It analysed whether colchicine could lower the risk of severe complications linked to Covid-19.

COLCORONA had approximately 4,500 Covid-19 patients who were not hospitalised at the time of enrolment and had minimum of one risk factor for Covid-19 complications.

According to the study results obtained from 4,488 patients, colchicine lowered the risk of death or hospitalisations by 21% in Covid-19 patients versus placebo, approaching statistical significance.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the analysis of the 4,159 Covid-19 patients receiving colchicine showed statistically significant reductions in the risk of death or hospitalisation versus placebo.

In these Covid-19 patients, the drug lowered hospitalisations by 25%, the requirement for mechanical ventilation by 50% and deaths by 44%.

The Institute noted that the latest scientific discovery makes colchicine the world’s first oral drug which can be used for treating non-hospitalised Covid-19 patients.

MHI Research Center Director, Université de Montréal Medicine professor and COLCORONA trial principal investigator Dr Jean-Claude Tardif said: “Our research shows the efficacy of colchicine treatment in preventing the ‘cytokine storm’ phenomenon and reducing the complications associated with Covid-19.

“We are pleased to offer the first oral medication in the world whose use could have a significant impact on public health and potentially prevent Covid-19 complications for millions of patients.

“Our innovative research programme also proves that the Montreal Heart Institute can make rapid scientific breakthroughs in a way that is economically viable for patients by repurposing existing drugs.

Colchicine treatment can aid in alleviating hospital congestion and cut down healthcare costs, the Institute noted.